What Is Monoclonal Gammopathy as a PACT Act Presumptive?
Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell disorder characterized by the presence of an abnormal protein — a monoclonal immunoglobulin (M-protein) — in the blood, without the organ damage or malignant proliferation that defines multiple myeloma. While MGUS itself may cause few symptoms, it represents a spectrum of plasma cell dysfunction that can progress to more serious hematologic malignancies.
For veterans with qualifying toxic exposure histories under the PACT Act, MGUS is recognized as a presumptive service-connected condition — meaning the VA presumes service connection without requiring direct proof of causation. This is a significant benefit, as establishing a causal link between military service and a hematologic condition would otherwise require extensive and often unavailable exposure data.
Veterans with MGUS should be aware that the condition requires regular monitoring, that its presence qualifies for VA service connection and compensation, and that progression to multiple myeloma or related conditions produces dramatically higher ratings.
Why the VA Recognizes This Connection
Burn pit chemical exposure. Open burn pits used throughout Southwest Asia exposed veterans to benzene, dioxins, and other known hematopoietic carcinogens — chemicals that damage the bone marrow stem cells responsible for producing blood cells and plasma cells. Benzene exposure in particular is a well-established risk factor for plasma cell dyscrasia.
Radiofrequency and radar exposures. Veterans with military occupational specialties involving radar, communications, and electronic equipment have elevated exposures to radiofrequency radiation, which has been studied as a potential contributor to hematologic conditions.
Chemical warfare agents and solvents. Gulf War veterans had documented exposures to organophosphate compounds and industrial solvents — several of which have known or suspected hematopoietic toxicity.
Cumulative occupational exposures. Military service involves numerous chemical exposures — from fuels, solvents, and propellants to pesticides and heavy metals — that cumulatively affect bone marrow function in ways that may manifest as plasma cell dyscrasia years after service.
The VA's PACT Act resources detail the presumptive condition list and qualifying service criteria.
Evidence That Wins This Claim
For the presumptive pathway:
- Proof of qualifying service: DD-214 documenting service in covered locations on or after August 2, 1990.
- MGUS diagnosis: Laboratory records showing a positive serum protein electrophoresis (SPEP) with M-protein quantification, confirmed by a hematologist.
- Hematology evaluation: An oncologist's or hematologist's assessment documenting MGUS diagnosis, M-protein level, and follow-up monitoring plan.
Supporting documentation:
- Bone marrow biopsy records: If performed, confirms the diagnosis and rules out progression.
- Serum free light chain ratio and immunofixation: Additional lab studies that characterize the MGUS and risk-stratify progression risk.
- Personal exposure statement: A description of toxic exposures during service — burn pit proximity, chemical exposures — supports the record even under the presumptive framework.
How the VA Rates Monoclonal Gammopathy
MGUS is rated under DC 7716 (Multiple Myeloma) or under malignant neoplasm codes:
Veterans should file for rating updates as the condition progresses. Progression to active myeloma typically produces a 100% rating during treatment phases.
Why These Claims Get Denied — And How to Prevent It
Qualifying service not verified. Ensure your service records clearly document deployment to covered locations. If DD-214 does not reflect relevant service, buddy statements and unit records may supplement the evidence.
Diagnosis not confirmed by a specialist. A primary care note mentioning elevated protein is insufficient. Hematology evaluation with formal MGUS diagnosis is required.
PACT Act eligibility not recognized by rater. Some claims processors are not fully familiar with PACT Act presumptive lists. Citing the specific regulatory authority (38 CFR § 3.309(f)) in the claim submission helps ensure the presumptive theory is recognized.
No rating requested despite 0% diagnosis. Even a 0% MGUS rating establishes service connection — which becomes critical if the condition progresses to multiple myeloma. Filing for service connection even at 0% creates the legal foundation for future increased ratings.
Monitoring burden not rated. Some veterans do not realize that monitoring requirements from MGUS — regular blood tests, hematology visits — themselves reflect a rated condition. Ensure the full functional impact is documented.
Related Conditions
- Respiratory Cancers PACT Act
- Kidney Cancer PACT Act
- Glioblastoma PACT Act Presumptive
- Hypertension PACT Act Presumptive
- Asthma PACT Act Presumptive
Next Steps
For a complete guide to PACT Act presumptive claims, see the PACT Act Playbook.
This is educational content, not legal advice. SecondaryClaims.com is not accredited by the VA under 38 CFR § 14.629. For accredited representation, consult a VA-accredited VSO, claims agent, or attorney at https://www.va.gov/ogc/apps/accreditation/.